Crinetics Pharmaceuticals (CRNX) Interest & Investment Income: 2017-2025
Historic Interest & Investment Income for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Sep 2025 value amounting to $12.5 million.
- Crinetics Pharmaceuticals' Interest & Investment Income rose 13.97% to $12.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.2 million, marking a year-over-year increase of 63.37%. This contributed to the annual value of $41.4 million for FY2024, which is 208.39% up from last year.
- Latest data reveals that Crinetics Pharmaceuticals reported Interest & Investment Income of $12.5 million as of Q3 2025, which was down 6.77% from $13.5 million recorded in Q2 2025.
- Over the past 5 years, Crinetics Pharmaceuticals' Interest & Investment Income peaked at $14.8 million during Q1 2025, and registered a low of $23,000 during Q4 2021.
- Its 3-year average for Interest & Investment Income is $8.7 million, with a median of $8.7 million in 2024.
- Its Interest & Investment Income has fluctuated over the past 5 years, first slumped by 94.60% in 2021, then surged by 8,178.26% in 2022.
- Over the past 5 years, Crinetics Pharmaceuticals' Interest & Investment Income (Quarterly) stood at $23,000 in 2021, then surged by 8,178.26% to $1.9 million in 2022, then skyrocketed by 253.05% to $6.7 million in 2023, then spiked by 113.75% to $14.4 million in 2024, then climbed by 13.97% to $12.5 million in 2025.
- Its Interest & Investment Income was $12.5 million in Q3 2025, compared to $13.5 million in Q2 2025 and $14.8 million in Q1 2025.